Eledon Pharmaceuticals (ELDN) Non-Current Assets (2013 - 2026)

Eledon Pharmaceuticals' Non-Current Assets history runs 14 years deep, the most recent figure standing at $33.1 million for Q1 2026.

• Quarterly Non-Current Assets fell 1.48% year-over-year to $33.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133.5 million (changed 0.09% YoY) and the FY2025 annual result came in at $33.3 million, down 1.05% from the prior year.
• Non-Current Assets was $33.1 million for Q1 2026 at Eledon Pharmaceuticals, down from $33.3 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $82.1 million in Q1 2022 and bottomed at $32.8 million in Q1 2024.
• A 5-year average of $41.9 million and a median of $33.3 million in 2025 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2023 — Non-Current Assets tumbled 59.67% — and 2025, when it increased 2.28%.
• Eledon Pharmaceuticals' Non-Current Assets stood at $33.3 million in 2022, then dropped by 1.02% to $32.9 million in 2023, then grew by 2.24% to $33.7 million in 2024, then slipped by 1.05% to $33.3 million in 2025, then slipped by 0.68% to $33.1 million in 2026.
• Business Quant data shows ELDN's Non-Current Assets at $33.1 million in Q1 2026, $33.3 million in Q4 2025, and $33.6 million in Q3 2025.